X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11128) 11128
Newsletter (1499) 1499
Newspaper Article (761) 761
Publication (655) 655
Magazine Article (255) 255
Transcript (190) 190
Book Review (91) 91
Trade Publication Article (33) 33
Book / eBook (14) 14
Conference Proceeding (10) 10
Book Chapter (9) 9
Dissertation (9) 9
Reference (3) 3
Data Set (2) 2
Government Document (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8513) 8513
male (6200) 6200
anticholesteremic agents - therapeutic use (5799) 5799
anticholesteremic agents (5114) 5114
female (4723) 4723
middle aged (4072) 4072
cholesterol (4025) 4025
index medicus (3537) 3537
cholesterol - blood (3214) 3214
cholesterol, ldl - blood (3116) 3116
aged (2832) 2832
animals (2748) 2748
anticholesteremic agents - pharmacology (2612) 2612
adult (2596) 2596
hypercholesterolemia - drug therapy (2578) 2578
hypercholesterolemia (2069) 2069
risk factors (2058) 2058
anticholesteremic agents - administration & dosage (1775) 1775
cardiac & cardiovascular systems (1610) 1610
atherosclerosis (1576) 1576
low density lipoproteins (1563) 1563
triglycerides - blood (1548) 1548
statins (1518) 1518
treatment outcome (1495) 1495
hypercholesterolemia - blood (1462) 1462
research (1393) 1393
pharmacology & pharmacy (1381) 1381
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1373) 1373
cholesterol, hdl - blood (1357) 1357
simvastatin (1327) 1327
lipids (1292) 1292
rats (1284) 1284
anticholesteremic agents - adverse effects (1273) 1273
lipids - blood (1251) 1251
medicine, general & internal (1108) 1108
blood cholesterol (1054) 1054
atorvastatin (1040) 1040
prevention (1018) 1018
drug therapy (1001) 1001
atorvastatin calcium (983) 983
ezetimibe (980) 980
double-blind method (977) 977
drug therapy, combination (964) 964
cardiovascular agents (921) 921
coronary-heart-disease (914) 914
analysis (911) 911
peripheral vascular disease (875) 875
care and treatment (869) 869
health aspects (860) 860
pravastatin (860) 860
heptanoic acids - therapeutic use (854) 854
cardiovascular disease (852) 852
risk (823) 823
pyrroles - therapeutic use (822) 822
cardiovascular diseases - prevention & control (801) 801
coronary heart disease (771) 771
medical research (718) 718
lipoproteins (715) 715
diet (694) 694
mice (694) 694
simvastatin - therapeutic use (685) 685
cardiovascular diseases (681) 681
physiological aspects (677) 677
hyperlipidemias - drug therapy (673) 673
diabetes (671) 671
time factors (670) 670
dose-response relationship, drug (663) 663
nutrition & dietetics (630) 630
coronary disease - prevention & control (625) 625
cholesterol - metabolism (614) 614
liver - metabolism (606) 606
disease (603) 603
metabolism (603) 603
medicine, experimental (600) 600
cardiovascular-disease (596) 596
mortality (578) 578
endocrinology & metabolism (572) 572
pravastatin - therapeutic use (571) 571
hypercholesterolemia - complications (561) 561
triglycerides (551) 551
therapy (545) 545
biochemistry & molecular biology (544) 544
cardiovascular (542) 542
myocardial-infarction (541) 541
azetidines - therapeutic use (535) 535
clinical trials as topic (520) 520
hypolipidemic agents - therapeutic use (513) 513
biomarkers - blood (507) 507
follow-up studies (507) 507
prospective studies (507) 507
efficacy (506) 506
reports (504) 504
lovastatin - therapeutic use (497) 497
randomized controlled trials as topic (490) 490
lipoproteins - blood (489) 489
liver - drug effects (489) 489
safety (487) 487
aged, 80 and over (480) 480
density-lipoprotein cholesterol (473) 473
hyperlipoproteinemia type ii - drug therapy (473) 473
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12827) 12827
German (265) 265
Russian (121) 121
French (111) 111
Spanish (92) 92
Italian (86) 86
Japanese (61) 61
Chinese (57) 57
Swedish (45) 45
Polish (39) 39
Dutch (34) 34
Hungarian (24) 24
Czech (22) 22
Portuguese (19) 19
Norwegian (17) 17
Danish (15) 15
Finnish (7) 7
Hebrew (7) 7
Turkish (6) 6
Ukrainian (4) 4
Lithuanian (3) 3
Romanian (3) 3
Croatian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2013, Volume 33, Issue 9, pp. 2202 - 2211
OBJECTIVE—The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie its inverse correlation with... 
high-density lipoproteins, pre-ß | cholesterol | apolipoproteins | acute coronary syndrome | inflammation | REGRESSION | LECITHINCHOLESTEROL ACYLTRANSFERASE | CELLULAR CHOLESTEROL | HUMAN ATHEROSCLEROTIC PLAQUE | high-density lipoproteins, pre-beta | INTRAVENOUS-INFUSION | TRANSPORT | PERIPHERAL VASCULAR DISEASE | MICE | HEMATOLOGY | A-I | LECITHIN | Apolipoprotein A-I - pharmacology | Lipoproteins, HDL - pharmacokinetics | Up-Regulation | Anticholesteremic Agents - blood | Lipoproteins, HDL - blood | Cholesterol - blood | Humans | Cholesterol Esters - blood | Apolipoprotein A-I - pharmacokinetics | Lipoproteins, HDL - pharmacology | Biological Transport | Female | ATP Binding Cassette Transporter 1 | Macrophages - immunology | Cytokines - blood | Cell Line | Lipoproteins, HDL - administration & dosage | Rabbits | Anti-Inflammatory Agents - pharmacology | Inflammation Mediators - blood | Particle Size | Anticholesteremic Agents - pharmacokinetics | Macrophages - metabolism | Animals | ATP-Binding Cassette Transporters - drug effects | Anticholesteremic Agents - administration & dosage | ATP-Binding Cassette Transporters - blood | Cholesterol, HDL - blood | Macrophages - drug effects | Apolipoprotein A-I - administration & dosage | Mice | Infusions, Intravenous | Anticholesteremic Agents - pharmacology | Apolipoprotein A-I - blood
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 12/2012, Volume 100, pp. 50 - 61
Journal Article
Atherosclerosis, ISSN 0021-9150, 2008, Volume 204, Issue 2, pp. 476 - 482
Abstract Background Risk factors of cardiovascular disease such as lipid aberrations, hypertension, abdominal adiposity and elevations in systemic... 
Cardiovascular | Cardiovascular disease | Inflammation | Hyperlipidemia | Plant sterols | Omega-3 fatty acids | C-REACTIVE PROTEIN | MYOCARDIAL-INFARCTION | SUDDEN-DEATH | OMEGA-3-FATTY-ACIDS | RISK | PHYTOSTEROLS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | FISH-OIL | CORONARY-HEART-DISEASE | DOCOSAHEXAENOIC ACIDS | Blood Pressure | Body Composition | Hyperlipidemias - blood | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Hypolipidemic Agents - blood | Capsules | Lipids - blood | Anti-Inflammatory Agents - therapeutic use | Cardiovascular Diseases - blood | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Hyperlipidemias - diet therapy | Hyperlipidemias - physiopathology | Phytosterols - therapeutic use | Hyperlipidemias - complications | Fatty Acids, Omega-3 - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Double-Blind Method | Risk Assessment | Administration, Oral | Risk Factors | Inflammation Mediators - blood | Treatment Outcome | Anti-Inflammatory Agents - blood | Phytosterols - administration & dosage | Phytosterols - blood | Hypolipidemic Agents - administration & dosage | Fatty Acids, Omega-3 - therapeutic use | Fatty Acids, Omega-3 - blood | Aged | Hypolipidemic Agents - therapeutic use | Dietary Supplements | Hypertension | Unsaturated fatty acids | Anti-inflammatory drugs | Analysis | Phytosterols | Anticholesteremic agents | Atherosclerosis
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2013, Volume 15, Issue 11, pp. 1040 - 1048
Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady‐state liraglutide 1.8 mg... 
antidiabetic drug | lipid‐lowering therapy | GLP‐1 analogue | phase I‐II study | type II diabetes | randomized trial | Type II diabetes | Randomized trial | Antidiabetic drug | Lipid-lowering therapy | GLP-1 analogue | Phase I-II study | LIPEMIA | OXIDATIVE STRESS | RECEPTOR AGONISTS | EXENATIDE | ACID BREATH TEST | INSULIN RESPONSES | MELLITUS | lipid-lowering therapy | phase I-II study | THERAPY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | GLUCAGON | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diet, High-Fat - adverse effects | Half-Life | Glucagon-Like Peptide 1 - blood | Male | Hypoglycemic Agents - blood | Cardiovascular Diseases - complications | Hypolipidemic Agents - blood | Lipids - blood | Postprandial Period | Cardiovascular Diseases - epidemiology | Female | Glucagon-Like Peptide 1 - pharmacokinetics | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - adverse effects | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Risk Factors | Hyperlipidemias - prevention & control | Germany - epidemiology | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Hyperlipidemias - etiology | Denmark - epidemiology | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypolipidemic Agents - pharmacokinetics | Hypoglycemic Agents - adverse effects | Liraglutide | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Triglycerides | Glucose | Fatty acids | Cholesterol | Dextrose | Glucose metabolism | Hypoglycemic agents | Diabetes therapy | Lipids | Diet | Apolipoproteins
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 02/2016, Volume 13, Issue 2, pp. 557 - 567
The oral route of administration is still by far the most ubiquitous method of drug delivery. Development in this area still faces many challenges due to the... 
oral dosage | motility | migrating motor complex | mechanistic physiological model | gastric emptying | bioequivalence | clinical trial simulation | MEDICINE, RESEARCH & EXPERIMENTAL | BOWEL WATER-CONTENT | TRANSIT | HUMAN SMALL-INTESTINE | HEALTHY-SUBJECTS | PHASE-III | HUMANS | PHARMACEUTICAL DOSAGE FORMS | MODEL | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | ABSORPTION | Anticholesteremic Agents - blood | Fatty Acids, Monounsaturated - administration & dosage | Humans | Immunosuppressive Agents - pharmacokinetics | Intestinal Absorption - drug effects | Gastrointestinal Motility - drug effects | Male | Indoles - administration & dosage | Tissue Distribution | Fluorouracil - administration & dosage | Immunosuppressive Agents - blood | Fluorouracil - blood | Computer Simulation | Diethylcarbamazine - blood | Lipoxygenase Inhibitors - blood | Fatty Acids, Monounsaturated - blood | Immunosuppressive Agents - administration & dosage | Diethylcarbamazine - pharmacokinetics | Administration, Oral | Diethylcarbamazine - administration & dosage | Indoles - blood | Gastrointestinal Transit - drug effects | Lipoxygenase Inhibitors - administration & dosage | Anticholesteremic Agents - pharmacokinetics | Lipoxygenase Inhibitors - pharmacokinetics | Gastric Emptying - drug effects | Models, Biological | Anticholesteremic Agents - administration & dosage | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Fluorouracil - pharmacokinetics
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 03/2012, Volume 287, Issue 14, pp. 11090 - 11097
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 09/2018, Volume 159, pp. 272 - 281
Cardiovascular disease is a leading cause of morbidity, mortality, and healthcare expenditure worldwide. Importantly, there is interindividual variation in... 
Atorvastatin | Clopidogrel | Bisoprolol | Assay validation | Liquid chromatography-mass spectrometry | CHEMISTRY, ANALYTICAL | METABOLITES | ACID | HUMAN PLASMA | QUANTITATION | TANDEM MASS-SPECTROMETRY | INDUCED MYOPATHY | LIQUID-CHROMATOGRAPHY | PHARMACOKINETICS | DISEASE | LACTONE FORMS | PHARMACOLOGY & PHARMACY | Prospective Studies | Ticlopidine - therapeutic use | Anticholesteremic Agents - blood | Chromatography, High Pressure Liquid - standards | Bisoprolol - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Male | Tandem Mass Spectrometry - trends | Platelet Aggregation Inhibitors - blood | Cardiovascular Diseases - blood | Chromatography, High Pressure Liquid - trends | Female | Atorvastatin - blood | Platelet Aggregation Inhibitors - therapeutic use | Mass Spectrometry - standards | Reproducibility of Results | Tandem Mass Spectrometry - standards | Mass Spectrometry - trends | Atorvastatin - therapeutic use | Antihypertensive Agents - therapeutic use | Ticlopidine - analogs & derivatives | Antihypertensive Agents - blood | Anticholesteremic Agents - therapeutic use | Bisoprolol - blood | Cohort Studies | Ticlopidine - blood | Medical research | Mortality | Organic acids | Antilipemic agents | Metabolites | Cardiac patients | Formic acid | Medicine, Experimental | Nitriles | Precipitation (Meteorology) | Acetic acid | Mass spectrometry | Methods | High performance liquid chromatography | Medical care, Cost of
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 04/2016, Volume 36, Issue 4, pp. 736 - 742
Journal Article
Free Radical Biology and Medicine, ISSN 0891-5849, 2007, Volume 43, Issue 9, pp. 1255 - 1262
The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the... 
Oxidative stress | ADMA | sRAGE | Free radicals | Hyperlipidemia | Statins | free radicals | ENDOTHELIAL DYSFUNCTION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ATHEROSCLEROSIS | INDUCED VASCULAR INJURY | RECEPTOR | RISK | ASYMMETRIC DIMETHYLARGININE ADMA | statins | ENDOCRINOLOGY & METABOLISM | ENDPRODUCTS | oxidative stress | CORONARY-ARTERY-DISEASE | GLYCATION END-PRODUCTS | Dinoprost - blood | Anticholesteremic Agents - blood | Heptanoic Acids - therapeutic use | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Hypercholesterolemia - urine | Nitric Oxide Synthase - antagonists & inhibitors | Male | Hypercholesterolemia - drug therapy | Arginine - analogs & derivatives | Female | Dinoprost - analogs & derivatives | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Receptor for Advanced Glycation End Products | Receptors, Immunologic - blood | Nitric Oxide - biosynthesis | Hypercholesterolemia - blood | Atherosclerosis - drug therapy | Cross-Sectional Studies | Dinoprost - urine | Double-Blind Method | Pyrroles - blood | Atherosclerosis - blood | Atorvastatin Calcium | Pravastatin - blood | Anticholesteremic Agents - therapeutic use | Arginine - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Nitric Oxide Synthase - metabolism | Heptanoic Acids - blood | Care and treatment | Hypercholesterolemia | Analysis | Low density lipoproteins | Nitrogen compounds | Knowledge-based systems | Cholesterol | Cardiovascular agents
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2015, Volume 210, pp. 160 - 168
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 09/2015, Volume 114, Issue 11, pp. 1807 - 1818
Journal Article